Every Form 4 that SILENCE THERAPEUTICS (SLNCF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SLNCF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLNCF filings page.
Griffiths Richard Ian reported acquisition or exercise transactions in a Form 4 filing for SLN. The filing lists transactions totaling 5,484,320 shares from August 10, 2026 to August 10, 2026.
Silence Therapeutics plc 10% owner Richard Ian Griffiths reported a series of open-market sales of American Depositary Shares (ADSs) associated with his holdings. Across six transactions between June 29 and July 6, 2026, entities linked to him sold an aggregate of 1,544,374 ADSs.
The ADSs were sold indirectly through interests, including Cream Capital Limited, with Griffiths disclaiming beneficial ownership beyond his proportionate pecuniary interest. Following these transactions, he continued to report 10,281,486 ADSs held indirectly. Each ADS is immediately convertible into three ordinary shares for no consideration and has no expiration date.
Silence Therapeutics plc’s 10% owner reported internal ADS transfers with no net change in economic exposure. On August 3, 2025, Ora Capital Limited sold 20,000 American Depositary Shares (ADS) at $5.45 per ADS while Richard Ian Griffiths purchased the same amount. On October 27, 2025, OCL sold a further 2,000 ADS at $7.75 per ADS, again matched by Griffiths buying 2,000 ADS. The filing states these are essentially internal transfers with no change in total beneficial holding, and that each ADS is convertible into three ordinary shares for no consideration.